Plasma NfL Elevation Secondary to BBB-Associated Transport Dysfunction Enables Longitudinal Neurodegeneration Tracking
🧪 Overview
Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF and ultimately into peripheral blood via degraded BBB transport mechanisms. Early BBB disruption increases permeability of neurofilament-derived peptides into circulation, causing disproportionate plasma NfL elevation relative to CSF levels. This makes plasma NfL a sensitive indicator of BBB permeability-augmented neurodegeneration, enabling peripheral blood-based disease progression monitoring. Multiple FDA-cleared platforms (Simoa, Elecsys, Lumipulse) provide validated detection.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Neurofilament Light<br/>Chain Release"]
B["Damaged<br/>Neurofilaments"]
C["Extracellular<br/>CSF Flow"]
D["BBB Transport<br/>Dysfunction"]
E["Peripheral Blood<br/>NfL Elevation"]
F["Longitudinal Neurodegeneration<br/>Tracking"]
B --> A
A --> C
C --> D
D --> E
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#e65100,stroke:#ffab91,color:#ffab91
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NEFL
No curated PDB or AlphaFold mapping for NEFL yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NEFL from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NEFL.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF plasma NfL is measured every 6 months over 24 months in patients with evidence of active neurodegeneration vs neurologically stable controls, THEN plasma NfL percent change will correlate with long | Spearman correlation ρ≥0.50 between plasma NfL percent change and percent brain volume loss (FreeSurfer) over 24 months in active neurodegeneration group; ≥80% | — no observation — | pending | 0.71 |
| IF participants are stratified by quantitative BBB permeability measured via dynamic contrast-enhanced MRI (DCE-MRI) to identify high-permeability (BBB-disrupted) vs low-permeability (BBB-intact) grou | Plasma NfL/CSF NfL ratio ≥2-fold greater in high-BBB-permeability group (mean plasma NfL/CSF NfL ratio: ≥0.8) compared to low-permeability group (mean ratio: ≤0 | — no observation — | pending | 0.68 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |